Company Profile

BioHelix Corporation
Profile last edited on: 2/1/19      CAGE: 34XN5      UEI:

Business Identifier: Molecular diagnostic tests based on proprietary isothermal Helicase Dependent Amplification (HDA) technology
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

500 Cummings Suite 5550
Beverly, MA 01915
   (978) 927-5056
Location: Single
Congr. District: 06
County: Essex

Public Profile

Originally founded as a spin-off from New England Biolabs, Inc, in May 2013, Biohelix Corporation was acquired by Quidel Corporation. Biohelix Corporation had been developing nucleic acid technologies for molecular diagnostics. These included a simple, cost-effective molecular diagnostic system called IsoAmp® for infectious diseases that takes advantage of the simplicity of an isothermal reaction and a disposable vertical-flow detection device. The lead product, the IsoAmp® HSV Assay, received FDA clearance in September 2011 for detecting genital and oral herpes under a moderate complexity label. among other simple molecular diagnostic tests for the near patient setting, the firm offers in vitro diagnostic products, such as IsoAmp, an herpes simplex viruses (HSV) assay test for the direct, qualitative detection of HSV DNA in male and female genital and oral lesions. The company also provides isothermal nucleic acid amplification solutions, including Rapisome pWGA kit, a whole genome amplification solution; IsoAmpII tHDA kit, a target sequence amplification solution; IsoAmpIII tHDA kit, a robust target amplification solution; and BESt Cassette, an express strip amplicon detection cassette. In addition, it offers Primer Navigator, a DNA amplification enhancer; and helicases, including helicase dependant amplification platform and primase-based whole genome amplification platform. Further, the company provides amplification enhancer reagents to improve all types of nucleic acid amplification reactions

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $600,000
Project Title: Low-Cost; Rapid Quantitative Isothermal Assay for Hiv Rna Using Zna
2012 2 NIH $482,810
Project Title: Integrated Molecular Diagnostic System for the Point-Of-Care
2011 2 NIH $546,867
Project Title: Molecular Tests for Malaria That Can Be Performed with Unprocessed Samples
2011 2 NIH $2,920,436
Project Title: Helicase-based rapid DNA diagnostic for Biodefense
2011 2 NIH $2,986,442
Project Title: Low cost molecular assay for HIV

Key People / Management

  Huimin Kong -- President/CEO

  Bertrand Lemieux -- Director of Technology Innovation

  Ying Li